XML 23 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaborative Agreements (Details 6) (USD $)
3 Months Ended 9 Months Ended 15 Months Ended 1 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Mar. 31, 2014
Mar. 31, 2015
Jan. 31, 2014
Jun. 30, 2014
Collaborative Agreements disclosures              
License fee revenue $ 5,078,000imgn_LicenseAndMilestoneFees $ 305,000imgn_LicenseAndMilestoneFees $ 52,729,000imgn_LicenseAndMilestoneFees $ 39,150,000imgn_LicenseAndMilestoneFees      
Arrangement consideration included in long-term deferred revenue 40,917,000us-gaap_DeferredRevenueNoncurrent   40,917,000us-gaap_DeferredRevenueNoncurrent   40,917,000us-gaap_DeferredRevenueNoncurrent   58,969,000us-gaap_DeferredRevenueNoncurrent
CytomX              
Collaborative Agreements disclosures              
Payments received under collaboration agreement         13,100,000us-gaap_ProceedsFromCollaborators
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
   
License fee revenue         0imgn_LicenseAndMilestoneFees
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
   
Arrangement consideration included in long-term deferred revenue 13,000,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
  13,000,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
  13,000,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
   
CytomX | Future Technological Improvements              
Collaborative Agreements disclosures              
Payments received under collaboration agreement         350,000us-gaap_ProceedsFromCollaborators
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_FutureTechnologicalImprovementsMember
   
Fair value of consideration for services received           310,000imgn_CollaborativeArrangementConsiderationPayableFairValue
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_FutureTechnologicalImprovementsMember
 
CytomX | Research Services              
Collaborative Agreements disclosures              
Payments received under collaboration agreement         140,000us-gaap_ProceedsFromCollaborators
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_ResearchServicesMember
   
Fair value of consideration for services received           12,800,000imgn_CollaborativeArrangementConsiderationPayableFairValue
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_ResearchServicesMember
 
CytomX | Right-to-test agreement              
Collaborative Agreements disclosures              
Payments received under collaboration agreement         13,000,000us-gaap_ProceedsFromCollaborators
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ us-gaap_TypeOfArrangementAxis
= imgn_RightToTestMember
0us-gaap_ProceedsFromCollaborators
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ us-gaap_TypeOfArrangementAxis
= imgn_RightToTestMember
 
CytomX | Development and Commercialization License              
Collaborative Agreements disclosures              
Payments received under collaboration agreement         12,700,000us-gaap_ProceedsFromCollaborators
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
   
Discount rate (as a percent)     13.00%us-gaap_FairValueInputsDiscountRate
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
       
Estimated utilization period after commercialization     10 years        
Estimated term of development and commercialization license     25 years        
CytomX | Development and Commercialization License | Maximum              
Collaborative Agreements disclosures              
Potential milestone payments           160,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
Potential milestone payments to be paid           80,000,000imgn_CollaborativeArrangementPotentialMilestonePaymentsPayable
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
CytomX | Development and Commercialization License | Development milestones | Maximum              
Collaborative Agreements disclosures              
Potential milestone payments           10,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_DevelopmentMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
Potential milestone payments to be paid           7,000,000imgn_CollaborativeArrangementPotentialMilestonePaymentsPayable
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_DevelopmentMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
CytomX | Development and Commercialization License | Development milestones | Phase I clinical trial              
Collaborative Agreements disclosures              
Potential milestone payments 1,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_DevelopmentPhaseAxis
= imgn_PhaseIClinicalTrialMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
  1,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_DevelopmentPhaseAxis
= imgn_PhaseIClinicalTrialMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
  1,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_DevelopmentPhaseAxis
= imgn_PhaseIClinicalTrialMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
   
Potential milestone payments to be paid           1,000,000imgn_CollaborativeArrangementPotentialMilestonePaymentsPayable
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_DevelopmentPhaseAxis
= imgn_PhaseIClinicalTrialMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
CytomX | Development and Commercialization License | Regulatory milestones | Maximum              
Collaborative Agreements disclosures              
Potential milestone payments           50,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_RegulatoryMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
Potential milestone payments to be paid           23,000,000imgn_CollaborativeArrangementPotentialMilestonePaymentsPayable
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_RegulatoryMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
CytomX | Development and Commercialization License | Sales milestones | Maximum              
Collaborative Agreements disclosures              
Potential milestone payments           100,000,000imgn_CollaborativeArrangementMilestonePaymentsPotential
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_SalesMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember
 
Potential milestone payments to be paid           $ 50,000,000imgn_CollaborativeArrangementPotentialMilestonePaymentsPayable
/ us-gaap_CounterpartyNameAxis
= imgn_CytomXTherapeuticsIncMember
/ imgn_MilestonePaymentsCategoryAxis
= imgn_SalesMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= imgn_DevelopmentAndCommercializationLicenseMember